DK2318530T3 - Ny epitop til immunisering mod influenzavirus - Google Patents

Ny epitop til immunisering mod influenzavirus Download PDF

Info

Publication number
DK2318530T3
DK2318530T3 DK09797336.6T DK09797336T DK2318530T3 DK 2318530 T3 DK2318530 T3 DK 2318530T3 DK 09797336 T DK09797336 T DK 09797336T DK 2318530 T3 DK2318530 T3 DK 2318530T3
Authority
DK
Denmark
Prior art keywords
plant
influenza
virus
seq
protein
Prior art date
Application number
DK09797336.6T
Other languages
English (en)
Inventor
Manon Couture
Louis-Philippe Vezina
Nathalie Landry
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Application granted granted Critical
Publication of DK2318530T3 publication Critical patent/DK2318530T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Claims (15)

  1. NY EPITOP TIL IMMUNISERING MOD INFLUENZA VIRUS Patentkrav
    1. Nukleinsyre omfattende en nukleotidsekvens, der koder for en influenzavirus-hemagglutinin (HA) omfattende et HA 1-domæne, hvori HA 1-domænet er modificeret, så det er fri for N-koblede glycosyleringssteder på position 154,165 og 286, ved a. modificering af position 154, så den koder for en ikke-asparagin og/eller modificering af position 156, så den koder for en ikke-serin eller ikke-threonin; b. modificering af position 165, så den koder for en ikke-asparagin og/eller modificering af position 167, så den koder for en ikke-serin eller ikke-threonin; og c. modificering af position 286, så den koder for en ikke-asparagin og/eller modificering af position 288, så den koder for en ikke-serin eller ikke-threonin; hvori nummereringen er i overensstemmelse med stammen A/Vietnam/1194/04, og hvori nukleotidsekvensen er operationelt koblet til en regulerende region, der er aktiv i en plante.
  2. 2. Nukleinsyre ifølge krav 1, hvori den regulerende region er udvalgt fra gruppen bestående af plastocyanin-regulerende region; napin-promoter, cruciferin-promoteren eller en regulerende region opnået fra Ribulose 1,5-bisphosphatcarboxylase/oxygenase (RuBisCO), chlorophyll a/b-bindende protein, ST-LS, polyhedron-promoter og gp64-promoteren.
  3. 3. Nukleinsyre ifølge krav 1 eller 2, hvori nukleotidsekvensen er defineret ifølge SEQ ID NO. 17, hvori rester, der koder for aminosyrer på position 154, 165 og 286, koder for en ikke-asparagin.
  4. 4. Nukleinsyre ifølge krav 1 eller 2, hvori nukleotidsekvensen er defineret ifølge SEQ ID NO. 17, hvori rester, der koder for aminosyrer på position 156, 167 og 288, koder for en ikke-serin, ikke-threonin eller en alanin.
  5. 5. Nukleinsyre som defineret i krav 1, hvori nukleotidsekvensen er defineret ifølge SEQ ID NO. 29.
  6. 6. Nukleinsyre ifølge krav 1, hvori nukleotidsekvensen koder for en influenzavirus-hemagglutinin (HA) omfattende sekvensen SEQ ID NO. 34, og hvori aminosyrer på position 154, 165 og 286 koder for en ikke-asparagin.
  7. 7. Nukleinsyre ifølge krav 6, hvori aminosyrer på position 156, 167 og 288 koder for en ikke-serin, en ikke-threonin eller en alanin.
  8. 8. Fremgangsmåde til fremstilling af influenzaviruslignende partikler (VLP’er) i en plant, en del deraf eller en plantecelle, hvilken fremgangsmåde omfatter: a) indføring af nukleinsyren ifølge et hvilket som helst af kravene 1 til 7 i planten, delen deraf eller plantecellen og b) inkubation af planten, delen deraf eller plantecellen under betingelser, der tillader ekspression af nukleinsyren, hvorved der dannes de VLP’er, hvori nukleinsyren enten udtrykkes forbigående i planten, delen deraf eller plantecellen eller udtrykkes stabilt i planten, delen deraf eller plantecellen; c) eventuelt høst af planten, delen deraf eller plantecellen og oprensning af VLP’eme.
  9. 9. Viruslignende partikel (VLP) omfattende et influenza-hemagglutinin (HA)-molekyle, som kodes for af nukleinsyren ifølge krav 1.
  10. 10. Viruslignende partikel (VLP) fremstillet ved fremgangsmåden ifølge krav 8.
  11. 11. VLP ifølge krav 9 eller 10, hvori glycosyleringsstedet består af en glycosyleringsgenkendelsestriade N-X-S/T hvori N er asparagin, X er en hvilken som helst aminosyre undtagen prolin, S er serin og T er threonin, eller asparagin-resten er erstattet med en ikke-asparagin-aminosyre, eller threonin-resten, der indgår i glycosyleringsgenkendelsestriaden N-X-S/T er erstattet med en ikke-serin- og ikke-threonin-aminosyre eller en kombination deraf.
  12. 12. VLP ifølge et hvilket som helst af kravene 9 til 11, hvori influenzaen er af type A og type B, eller HA’et er fra en eller mere end en A-undertype udvalgt fra gruppen bestående af: Hl, H2, H3, H4, H5, H6, H7, H8, H9, HIO, Hil, H12, H13, H14, H15 og H16.
  13. 13. VLP ifølge et hvilket som helst af kravene 9 til 12 til anvendelse som en vaccine til forebyggelse eller behandling af en virusinfektion hos et subjekt.
  14. 14. Sammensætning omfattende en effektiv dosis af en VLP ifølge et hvilket som helst af kravene 9 til 12 i en blanding med en farmaceutisk acceptabel bærer.
  15. 15. Transgen plante eller transgen plantecelle forbigående eller stabilt transformeret med nukleinsyren ifølge et hvilket som helst af kravene 1 til 7, hvori planten eller plantecellen indeholder nukleinsyren ifølge et hvilket som helst af kravene 1 til 7.
DK09797336.6T 2008-07-18 2009-07-15 Ny epitop til immunisering mod influenzavirus DK2318530T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8181108P 2008-07-18 2008-07-18
PCT/CA2009/001040 WO2010006452A1 (en) 2008-07-18 2009-07-15 New influenza virus immunizing epitope

Publications (1)

Publication Number Publication Date
DK2318530T3 true DK2318530T3 (da) 2016-10-03

Family

ID=41549982

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09797336.6T DK2318530T3 (da) 2008-07-18 2009-07-15 Ny epitop til immunisering mod influenzavirus

Country Status (19)

Country Link
US (1) US9546375B2 (da)
EP (1) EP2318530B1 (da)
JP (1) JP5813505B2 (da)
KR (1) KR101745925B1 (da)
CN (1) CN102165062B (da)
AU (1) AU2009270404B2 (da)
CA (1) CA2730668C (da)
DK (1) DK2318530T3 (da)
ES (1) ES2593277T3 (da)
HK (1) HK1156969A1 (da)
IL (1) IL210451A (da)
MX (2) MX370690B (da)
MY (1) MY161965A (da)
NZ (1) NZ590351A (da)
PT (1) PT2318530T (da)
RU (1) RU2546872C2 (da)
SG (1) SG192503A1 (da)
WO (1) WO2010006452A1 (da)
ZA (1) ZA201101231B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009202819B2 (en) 2007-07-13 2014-08-28 Aramis Biotechnologies Inc. Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
DK2294202T3 (da) * 2008-07-08 2015-08-31 Medicago Inc Opløselige rekombinante influenza-antigener
MY161965A (en) 2008-07-18 2017-05-15 Medicago Inc New influenza virus immunizing epitope
CA2762042C (en) 2009-06-24 2012-11-20 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
AU2010266129B2 (en) 2009-07-02 2016-04-14 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
DK2480560T3 (da) 2009-09-22 2018-04-16 Medicago Inc Fremgangsmåde til fremstilling af planteafledte proteiner
JP2013541528A (ja) 2010-09-21 2013-11-14 マサチューセッツ インスティテュート オブ テクノロジー ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置
CA2813078A1 (en) 2010-10-04 2012-04-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
WO2012088428A1 (en) * 2010-12-22 2012-06-28 Novavax Inc. Modified influenza hemagglutinin proteins and uses thereof
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
CA2839009C (en) * 2011-06-13 2015-10-20 Medicago Inc. Rabies virus like particle production in plants
NZ622731A (en) 2011-09-30 2016-04-29 Medicago Inc Increasing virus-like particle yield in plants
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
SG11201507928QA (en) 2013-03-28 2015-10-29 Medicago Inc Influenza virus-like particle production in plants
EP3039036B1 (en) 2013-08-28 2019-05-22 GlaxoSmithKline Biologicals S.A. Novel influenza antigens and antibodies
US10291197B2 (en) * 2016-02-03 2019-05-14 Cg Discovery, Inc. Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites and methods of use thereof
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3079486A1 (en) * 2017-10-18 2019-04-25 Xiamen University Mutant of hemagglutinin protein of h3n2 subtype influenza virus and use thereof
JP2021528970A (ja) * 2018-06-27 2021-10-28 メディカゴ インコーポレイテッド インフルエンザウイルスヘマグルチニン変異体

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
EP0203177A4 (en) 1984-11-29 1987-04-28 Scripps Clinic Res POLYPEPTIDES AND ANTIBODIES AGAINST DEGGLYCOSILIZED VIRAL GLYCOPROTEINS.
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5312746A (en) * 1993-01-08 1994-05-17 Life Technologies, Inc. Cloning and expressing restriction endonucleases and modification methylases from caryophanon
GB9414118D0 (en) 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
GB9524350D0 (en) 1995-11-29 1996-01-31 Lynxvale Ltd Enhancer-increased gene expression in plants
US6042832A (en) * 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US5945326A (en) * 1997-03-20 1999-08-31 New England Biolabs, Inc. Method for cloning and producing the Spel restriction endonuclease
US20010006950A1 (en) * 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6489537B1 (en) * 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001029242A2 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
JP4890712B2 (ja) 1999-10-26 2012-03-07 スティヒティング ディーンスト ランドバウクンディフ オンデルズーク 植物における哺乳類型グリコシレーション
MXPA03006426A (es) 2001-01-19 2003-09-22 Dow Chemical Co Metodo para produccion secretoria de glicoproteina que tiene cadena de azucar humana, utilizando celula de planta.
US7226774B2 (en) * 2002-02-13 2007-06-05 Wisconsin Alumni Research Foundation Signal for packaging of influenza virus vectors
NZ534880A (en) * 2002-03-19 2008-04-30 Plant Res Int Bv Optimizing glycan processing in plants
US7897842B2 (en) * 2002-03-19 2011-03-01 Plant Research International B.V. GnTIII expression in plants
US20040264870A1 (en) 2002-08-20 2004-12-30 Skunes Timothy A. Optical alignment mount with height adjustment
ES2574993T3 (es) 2003-01-22 2016-06-23 Roche Glycart Ag Construcciones de fusión y uso de las mismas para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
CA2524293A1 (en) 2003-05-05 2004-11-18 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
EP1633312A4 (en) * 2003-06-16 2012-09-26 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7723569B2 (en) 2004-04-30 2010-05-25 National Institute Of Agrobiological Sciences Method for producing ubiquinone-10 in plant
PL1883701T3 (pl) 2005-04-29 2012-06-29 Univ Cape Town Ekspresja białek wirusa w roślinach
AU2006270065A1 (en) 2005-07-19 2007-01-25 Dow Global Technologies Inc. Recombinant flu vaccines
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
TWI488968B (zh) 2005-10-18 2015-06-21 Novavax Inc 功能性流行性感冒類病毒顆粒（ＶＬＰｓ）
US20090169576A1 (en) * 2005-10-26 2009-07-02 Roberto Crea Influenza combinatorial antigen vaccine
KR20080106433A (ko) 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
BRPI0713671A2 (pt) * 2006-06-16 2013-12-03 Dow Agrosciences Llc Sequências de dna, vetores e proteínas de hemaglutinina de influenza aviária
NZ598417A (en) 2007-06-15 2013-06-28 Centre Nat Rech Scient Modifying glycoprotein production in plants
KR100964462B1 (ko) 2007-07-10 2010-06-16 성균관대학교산학협력단 형질전환 식물 유래의 조류독감 바이러스 백신 및 그 제조방법
AU2009202819B2 (en) 2007-07-13 2014-08-28 Aramis Biotechnologies Inc. Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
IL203018A (en) 2007-07-13 2015-01-29 Medicago Inc Influenza virus-like particles containing megalotinin produced in a plant
EA034733B1 (ru) 2008-01-21 2020-03-13 Медикаго Инк. Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
MY161965A (en) 2008-07-18 2017-05-15 Medicago Inc New influenza virus immunizing epitope

Also Published As

Publication number Publication date
MX370690B (es) 2019-12-19
ES2593277T3 (es) 2016-12-07
ZA201101231B (en) 2011-10-26
WO2010006452A1 (en) 2010-01-21
EP2318530B1 (en) 2016-06-22
AU2009270404B2 (en) 2015-01-29
RU2011105885A (ru) 2012-08-27
KR20110031966A (ko) 2011-03-29
KR101745925B1 (ko) 2017-06-12
CA2730668A1 (en) 2010-01-21
CA2730668C (en) 2020-04-28
RU2546872C2 (ru) 2015-04-10
JP5813505B2 (ja) 2015-11-17
HK1156969A1 (zh) 2012-06-22
PT2318530T (pt) 2016-09-30
MX2011000657A (es) 2011-03-21
SG192503A1 (en) 2013-08-30
MY161965A (en) 2017-05-15
IL210451A0 (en) 2011-03-31
US9546375B2 (en) 2017-01-17
IL210451A (en) 2015-04-30
CN102165062B (zh) 2017-09-08
EP2318530A4 (en) 2012-01-25
US20110191915A1 (en) 2011-08-04
CN102165062A (zh) 2011-08-24
NZ590351A (en) 2012-11-30
EP2318530A1 (en) 2011-05-11
JP2011528223A (ja) 2011-11-17
AU2009270404A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
DK2318530T3 (da) Ny epitop til immunisering mod influenzavirus
CA2693956C (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
CA2730185C (en) Influenza virus-like particles (vlps) comprising hemagglutinin
CA2707235C (en) Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CA2850407C (en) Increasing virus-like particle yield in plants
RU2569195C9 (ru) Химерные вирусоподобные частицы, содержащие гемагглютинин, сходные с частицами вируса гриппа
RU2569195C2 (ru) Химерные вирусоподобные частицы, содержащие гемагглютинин, сходные с частицами вируса гриппа
VEZINA et al. Patent 2730668 Summary
VEZINA et al. Patent 2730668 Summary
AU2015202195A1 (en) New influenza virus immunizing epitope
D'AOUST et al. Patent 2730185 Summary